---
title: "China Meheco: The application for the listing of hydrochlorothiazide has been approved"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247448760.md"
description: "China Meheco's wholly-owned subsidiary Tianfang Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug Urapidil Hydrochloride. This medication is primarily used to treat hypertensive crises, severe and very severe hypertension, as well as resistant hypertension, and can control perioperative hypertension"
datetime: "2025-07-07T08:12:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247448760.md)
  - [en](https://longbridge.com/en/news/247448760.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247448760.md)
generator: "portal-rs"
---

# China Meheco: The application for the listing of hydrochlorothiazide has been approved

According to the announcement from China Meheco (600056.SH), its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. (hereinafter referred to as "Tianfang Pharmaceutical") has recently received the "Approval Notice for the Application for Market Launch of Chemical Raw Materials" for Urapidil Hydrochloride (hereinafter referred to as "the drug") issued by the National Medical Products Administration (hereinafter referred to as "NMPA").

This drug is mainly used for the treatment of hypertensive crises (such as a sudden increase in blood pressure), severe and extremely severe hypertension, and refractory hypertension; it is also used to control perioperative hypertension

### Related Stocks

- [600056.CN](https://longbridge.com/en/quote/600056.CN.md)

## Related News & Research

- [Allan Green-controlled Candel & Partners buys 1,000 North Atlantic Energies shares at EUR 88.39](https://longbridge.com/en/news/298041557.md)
- [Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors](https://longbridge.com/en/news/297890174.md)
- [China Resources Pharma unit KPC wins registration to issue RMB 1 billion in medium-term notes](https://longbridge.com/en/news/297630970.md)
- [If space data centers feel far-fetched, why not interstellar travel?](https://longbridge.com/en/news/297632765.md)
- [Davide Leone & Partners takes 5.01% voting stake in SES](https://longbridge.com/en/news/297669363.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**